LUND, SE / ACCESS Newswire / November 3, 2025 / BioInvent International AB ("BioInvent")(STO:BINV)(Nasdaq Stockholm:BINV), a biotech company focused on the discovery and development of novel and first ...
Additionally, the more than 50 abstracts accepted at ASH include new and updated data from Incyte’s MPN, GVHD and hematology programs including interim safety data evaluating axatilimab (Niktimvo™) in ...
Session Name: 631. Myeloproliferative Syndromes and Chronic Myeloid Leukemia: Basic and Translational: Precision targeting in MPN Session Date and Time: December 6, 2025; 9:30 AM – 11:00 AM ...
SUMMIT data for bezuclastinib in NonAdvSM selected for two oral presentations which will describe its best-in-class potentialNovel JAK2 V617F ...
The interim data will be presented in an oral presentation at the 67 th American ... from 11:30 a.m. – 11:45 a.m. ET Ulviprubart (ABC008) is a first-in-class anti-KLRG1 antibody product candidate ...
Phase 3 PEAK results in 2nd-line GIST patients expected in November; pivotal APEX results in AdvSM patients expected in December ...
This latest pattern emphasizes competency-based learning, focusing on conceptual understanding, analytical thinking, and ...
Newspoint on MSN
CBSE releases School Academic Performance Report Card for promoting data-driven academic planning
The Central Board of Secondary Education (CBSE) has released the School Academic Performance Report Card for all ...
As Alphabet Inc.’s Google and other US tech behemoths pledge billions of dollars to build artificial intelligence ...
Compelling results set new clinical standard in generalized myasthenia gravis (gMG), increasing confidence in the Company’s registrational KYSA-6 Phase 3 MG trial. 100% of patie ...
“Apple reinvents the phone” was the message Steve Jobs wanted his audience to take away when he introduced the iPhone. That’s ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback